Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 5:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 3,924 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1Phase 2 Interventional Results available

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

NCT02437253
Conditions
Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
5 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Torrance, California
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Insomnia, Insomnia Due to Medical Condition, Cancer
Interventions
STEP-YA with Coaching, STEP-YA without Coaching
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
20 Years to 39 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neurofibromatosis 1
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Glioma, Brain Neoplasm
Interventions
131I-TM-601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
Birmingham, Alabama • Duarte, California • St Louis, Missouri
Conditions
Brain Tumor
Interventions
Visualase®
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
19 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Tumor
Interventions
ABT 510
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
pegfilgrastim, cisplatin, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Conditions
Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma
Interventions
Temodar and SCH 66336
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Myasthenia Gravis
Interventions
ARGX-113, Placebo
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Tampa, Florida + 3 more
Conditions
Breast Cancer, Depression, Anxiety, Mindfulness, Sleep Disturbance
Interventions
Mindfulness, Control group
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
No Longer Available No phase listed Expanded access

Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients

NCT02589912
Conditions
Neurofibromatosis Type 2, Severe Profound Sensorineural Hearing Loss
Interventions
Nucleus Profile ABI541 Auditory Brainstem Implant
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
12 Years to 80 Years
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Nociceptive Pain, Neuropathic Pain, Non-cancer Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor), Chondrosarcoma, Soft Tissue Sarcoma, Chordoma, Sarcoma, Carcinoma of Breast, Single Patient IND for Glioblastoma, Ovarian Carcinoma, Non-small Cell Lung Cancer , Prostate Cancer
Interventions
DNG64-CAR-V
Drug
Lead sponsor
Aveni Foundation
Other
Eligibility
12 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Ribociclib, Everolimus, Temozolomide (TMZ)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Months to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Conditions
Mandible Tumor, Mandibular Injuries, Mandible; Deformity
Interventions
EB-CMF
Combination Product
Lead sponsor
Epibone, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
San Francisco, California • Cleveland, Ohio • San Antonio, Texas
Conditions
Neurofibromatosis Type II
Interventions
Everolimus (RAD001) , Afinitor®
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Brain Tumors
Interventions
Induction therapy (Regimen 1, Course 1, Cycle A1, Regimen 1, Course 1, Cycle A2 (Days 22 - 42), Cycle B, Regimen 1, Course 2, Intrathecal Mafosfamide, Regimen 1 Course 2, IT mafosfamide, Regimen 2, Course 1, Regimen 2, Course, 1, Cycle C1, Regimen 2, Course 2, radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 36 Months
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Durham, North Carolina • Memphis, Tennessee • Houston, Texas
Completed No phase listed Observational Results available

Barrow Nasal Inventory Survey

NCT01322945
Conditions
Pituitary Tumors
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neurotoxicity Syndrome, Pain, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Cytology Specimen Collection Procedure, Pharmacological Study
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 15 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated No phase listed Observational Accepts healthy volunteers

Medical Treatment Decision Making Using Adaptive Conjoint Analysis

NCT02608307
Conditions
Cancer, Brain Tumor, Solid Tumor, Leukemia, Lymphoma
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee